SCM
LIMNW

Saba Capital Management’s Liminatus Pharma Warrants LIMNW Stock Holding History

Saba Capital Management’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Hold
233,761
– – ﹤0.01% 364
2026
Q1 		$11.5K Hold
233,761
– – ﹤0.01% 349
2025
Q4 		$8.94K Hold
233,761
– – ﹤0.01% 313
2025
Q3 		$34.6K Hold
233,761
– – ﹤0.01% 267
2025
Q2 		$56.1K Buy
+233,761
New +$45.9K ﹤0.01% 240

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Saba Capital Management's LIMNW Position: Q2 2026 in Review

Saba Capital Management held its Liminatus Pharma Warrants (LIMNW) position steady in Q2 2026 at 233,761 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #364.

Saba Capital Management first reported a position in LIMNW in Q2 2025 and has held it in 5 quarters since. The position peaked at $56.1K in Q2 2025. 22 funds tracked by Wall St. Rank hold LIMNW as of Q2 2026.

  • Saba Capital Management held 233,761 shares of Liminatus Pharma Warrants worth $11.9K as of Q2 2026.
  • Saba Capital Management left its Liminatus Pharma Warrants share count unchanged in Q2 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of Saba Capital Management's portfolio in Q2 2026, its #364 holding.
  • Saba Capital Management first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 5 quarters since.
  • Saba Capital Management's Liminatus Pharma Warrants position peaked at $56.1K in Q2 2025.
  • 22 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q2 2026.

Based on Saba Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.